Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Infectious Diseases

• Publication date

  2006-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1086/499364PMID 16392089
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.

  2006cited by this paper
• Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach

  2005cited by this paper
• Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral Therapy

  2005cited by this paper
• Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals

  2005cited by this paper
• Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.

  2004cited by this paper
• Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study

  2004influential reference
• Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

  2004cited by this paper
• A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.

  2004cited by this paper
• Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

  2004cited by this paper
• The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities.

  2004cited by this paper
• Pharmacokinetic and Pharmacodynamic Characteristics of Emtricitabine Support Its Once Daily Dosing for the Treatment of HIV Infection

  2004cited by this paper
• It Is Safe to Stop Antiretroviral Therapy in Patients With Preantiretroviral CD4 Cell Counts >250 cells/μL

  2004cited by this paper
• Treatment for adult HIV infection.

  2004cited by this paper
• Tenofovir Disoproxil Fumarate

  2004cited by this paper
• Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals

  2003cited by this paper
• A Multi-Investigator/Institutional DNA Bank for AIDS-Related Human Genetic Studies: AACTG Protocol A5128

  2003cited by this paper
• Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression

  2003cited by this paper
• Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

  2003cited by this paper
• Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

  2003cited by this paper
• Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography.

  2003cited by this paper
• Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 398

  2003cited by this paper
• The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity

  2003cited by this paper
• Population pharmacokinetic meta-analysis with efavirenz.

  2002cited by this paper
• Mixed-Effects Models in S and S-Plus

  2001cited by this paper
• Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.

  2001cited by this paper
• Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy

  2000cited by this paper
• Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.

  1999cited by this paper
• Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study.

  1999cited by this paper
• Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000

  1998cited by this paper
• HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

  1995cited by this paper
• The fastest genome evolution ever described: HIV variation in situ.

  1993cited by this paper
• Simulation of linear compartment models with application to nuclear medicine kinetic modeling.

  1988cited by this paper
• A new look at the statistical model identification

  1974cited by this paper

• Acceleration of infectious disease drug discovery and development using a humanized model of drug metabolism

  2024cites this paper
• A Physiologically-Based Pharmacokinetic Simulation to Evaluate Approaches to Mitigate Efavirenz-Induced Decrease in Levonorgestrel Exposure with a Contraceptive Implant

  2024cites this paper
• Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics

  2024cites this paper
• Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial.

  2024cites this paper
• Prenatal efavirenz exposure is independently associated with maternal, but not fetal CYP2B6 genotype

  2024cites this paper
• Oral Administration of Efavirenz Dysregulates the Tph2 Gene in Brain Serotonergic Areas and Alters Weight and Mood in Mice

  2024cites this paper
• A review of the effects of pharmaceutical pollutants on humans and aquatic ecosystem

  2024cites this paper
• Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz‐containing regimen

  2023cites this paper
• Impact of Obesity on the Drug–Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers

  2023cites this paper
• Influence of CYP2B6 and CYP3A4 polymorphisms on the virologic and immunologic responses of patients treated with efavirenz-containing regimen

  2022cites this paper
• Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide

  2022cites this paper
• Impact of pre-existent drug resistance on virological efficacy of single tablet regimens in people living with HIV.

  2022cites this paper
• Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana

  2021cites this paper
• Impact of Efavirenz Mid-dose Plasma Concentration on Long-Term Weight Change Among Virologically Suppressed People Living With HIV

  2021cites this paper
• HIV cell-to-cell spread slows evolution of drug resistance

  2020cites this paper
• Prevalence of Cytochrome P450 2B6 Single Nucleotide Polymorphism in an HIV-Positive Cohort in Jos, Nigeria: Implication for HIV Therapy

  2020cites this paper
• How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?

  2020cites this paper
• Pharmacogenomics and Psychopharmacology

  2020cites this paper
• Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

  2020cites this paper
• Management of Virologic Failure and Human Immunodeficiency Virus Drug Resistance.

  2019cites this paper
• Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers

  2019cites this paper
• Pharmacogenomic Considerations in the Treatment of HIV Infection

  2019cites this paper
• Proteomic insights into the modulation of foetal neurogenesis by the anti-retroviral efavirenz

  2019cites this paper
• Patterns of non-adherence to oral antiretroviral medication: frequencies of consecutively missed doses

  2019cites this paper
• Occurrence of CYP2B6 516G>T polymorphism in patients with ARV‐associated hepatotoxicity

  2019cites this paper
• Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs

  2018influential citation
• The Effect of Antiretroviral Stock‐Outs on Medication Adherence Among Patients Living With HIV in Ghana: A Qualitative Study

  2018cites this paper
• Human cytochrome P450 2B6 genetic variability in Botswana: a case of haplotype diversity and convergent phenotypes

  2018cites this paper
• Pharmacogenetics of Adverse Drug Reactions.

  2018cites this paper
• Cytochrome 2B6 polymorphism and efavirenz‐induced central nervous system symptoms : a substudy of the ANRS ALIZE trial

  2017cites this paper
• Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs

  2017cites this paper
• Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients

  2017cites this paper
• Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV

  2017cites this paper
• Relationship Between Adherence Rate Threshold and Drug ‘Forgiveness’

  2017cites this paper
• HIV-Positive-to-HIV-Positive Liver Transplantation.

  2016cites this paper
• Genotoxic and Cytotoxic Effects of Antiretroviral Combinations in Mice Bone Marrow

  2016cites this paper
• A pharmacist's role in the individualization of treatment of HIV patients.

  2016cites this paper
• Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection

  2016cites this paper
• Suicidal Behaviours During Efavirenz Treatment in HIV Positive Patients

  2016cites this paper
• Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments.

  2016influential citation
• Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers

  2016cites this paper
• CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women

  2016cites this paper
• Single Nucleotide Polymorphisms in Cellular Drug Transporters Are Associated with Intolerance to Antiretroviral Therapy in Brazilian HIV-1 Positive Individuals

  2016cites this paper
• Insights into CYP2B6-mediated drug–drug interactions

  2016cites this paper
• Relationship between Efavirenz plasma concentrations and CYP2B6 Polymorphism in HIV/TB co-infected Africans taking rifampicin in the treatment Antituberculosis at Abidjan.

  2015cites this paper
• CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon.

  2015influential citation
• Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice.

  2015cites this paper
• Efavirenz and the CNS: what we already know and questions that need to be answered.

  2015cites this paper
• Efavirenz Dosing: Influence of Drug Metabolizing Enzyme Polymorphisms and Concurrent Tuberculosis Treatment

  2015cites this paper
• Improvement of Depression and Anxiety After Discontinuation of Long- Term Efavirenz Treatment.

  2015cites this paper
• Pharmacogenetics as a tool to tailor antiretroviral therapy: A review.

  2015cites this paper
• 128 – Human Immunodeficiency Virus Infection in Women

  2015cites this paper
• Individualization of antiretroviral therapy - Pharmacogenomic aspect

  2015cites this paper
• Development of NanoART for HIV Treatment: Minding the Cytochrome P450 (CYP) Enzymes.

  2015cites this paper
• The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption

  2015cites this paper
• Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapy

  2015cites this paper
• Cytochrome P450 2J2, a new key enzyme in cyclophosphamide bioactivation and a potential biomarker for hematological malignancies

  2015cites this paper
• Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.

  2014cites this paper
• The Clinical Pharmacology of Human

  2014cites this paper
• Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz

  2014cites this paper
• Comparable Long-Term Efficacy of Lopinavir/Ritonavir and Similar Drug-Resistance Profiles in Different HIV-1 Subtypes

  2014cites this paper
• Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.

  2014cites this paper
• Therapeutic Drug Monitoring and Pharmacogenetic Study of HIV-Infected Ethnic Chinese Receiving Efavirenz-Containing Antiretroviral Therapy with or without Rifampicin-Based Anti-Tuberculous Therapy

  2014cites this paper
• Neurological and Psychiatric Adverse Effects of Antiretroviral Drugs

  2014cites this paper
• Insights from an individual-level model of HIV programmes in southern Africa : HIV testing, ART and resistance

  2014cites this paper
• Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach

  2014influential citation
• The clinical pharmacology of Human Immunodeficiency Virus (HIV) therapy failure

  2014influential citation
• Genetic variability of CYP2B6 polymorphisms in southeast Iranian population: implications for malaria and HIV/AIDS treatment.

  2014cites this paper
• Plasma Concentrations, Efficacy and Safety of Efavirenz in HIV-Infected Adults Treated for Tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA Trial)

  2014cites this paper
• Genetic and metabolic studies towards personalized conditioning regimen prior to stem cell transplantation

  2014cites this paper
• Projections of pharmacokinetic parameter estimates from mid-dose plasma concentrations in individuals on efavirenz: A novel approach

  2014cites this paper
• Deep sequencing of HIV: clinical and research applications.

  2014cites this paper
• Pharmacogenetics of antiretroviral therapy

  2014cites this paper
• Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance

  2013cites this paper
• Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions

  2013cites this paper
• Pharmacokinetic and Pharmacogenetic aspects of drug-drug interactions between antiretroviral and anti-tuberculosis drugs in Ethiopian patients: Implication for optimization of TB-HIV co-treatment

  2013cites this paper
• Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

  2013cites this paper
• Factors associated with remaining on initial randomized efavirenz-containing regimens

  2013cites this paper
• Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake Cessation: Implications for HIV Treatment and Prevention

  2013cites this paper
• By virtue of circumstance: HIV/AIDS in mobile and rural populations in Western Australia, an ethnographic study

  2013cites this paper
• Cytochrome P450 pharmacogenetics in African populations

  2013cites this paper
• Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose.

  2013cites this paper
• The Pharmacogenetics of HIV Treatment: A Practical Clinical Approach

  2013cites this paper
• impAct of non-Adherence to AntiretrovirAl combinAtion therApy in hiv-infected children

  2013cites this paper
• Antiretroviral Treatment Interruptions Induced by the Kenyan Postelection Crisis Are Associated With Virological Failure

  2013cites this paper
• forGiveness of non-Adherence to once vs. tWice dAily lAmivudine/AbAcAvir in combinAtion With efAvirenz in hiv-infected children

  2013cites this paper
• Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States

  2013cites this paper
• A Single Nucleotide Polymorphism in CYP 2 B 6 Leads to > 3-fold Increases in Efavirenz Concentrations in Intensive PK Curves and Hair Samples in HIV-infected Women

  2013cites this paper
• hiGhly Active AntiretrovirAl therApy in children

  2013cites this paper
• Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.

  2013cites this paper
• Prevalence of MDR1 C3435T and CYP2B6 G516T Polymorphisms among HIV-1 Infected South African Patients

  2012influential citation
• Review paper Antiretroviral drugs usage in HIV-positive pregnant women

  2012cites this paper
• A Pharmacogenomical perspective in HIV/AIDS Therapies

  2012cites this paper
• Combined Antiretroviral Therapy During Chemotherapy for HIV-Patients with Hodgkin and non-Hodgkin Lymphoma: A review of tolerability and survival outcomes

  2012influential citation
• Cytochrome P450 Polymorphisms

  2012cites this paper
• Allele and Genotype Frequencies of CYP2B6 and CYP2C19 Polymorphisms in Egyptian Agricultural Workers

  2012cites this paper
• NNRTIs: pharmacological data.

  2012cites this paper
• Antiretroviral drugs usage in HIV-positive pregnant women

  2012cites this paper
• Pharmacokinetic Parameters of Once-Daily Rilpivirine following Administration of Efavirenz in Healthy Subjects

  2012cites this paper
• A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.

  2012cites this paper